Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

被引:16
作者
Wang, Cong [1 ]
He, Miao [1 ]
Peng, Jiajia [1 ]
Li, Shengbing [1 ]
Long, Min [1 ]
Chen, Wenwen [1 ]
Liu, Dongfang [1 ]
Yang, Gangyi [1 ]
Zhang, Lili [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Chongqing 400010, Peoples R China
基金
中国国家自然科学基金;
关键词
Osteopontin; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus; ADIPOSE-TISSUE; NEUTROPHIL INFILTRATION; OBESITY; EXPRESSION; INFLAMMATION; PREVALENCE; STEATOSIS;
D O I
10.1016/j.cyto.2019.154837
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) commonly occurs in patients with type 2 diabetes mellitus (T2DM). Osteopontin (OPN) is a multifunctional protein with pleiotropic physiological functions. This study aimed to investigate the interrelation between circulating OPN and NAFLD in T2DM patients. Overall, 249 subjects were classified into 4 groups: 53 patients with NAFLD and T2DM; 57 with newly diagnosed T2DM; 59 with NAFLD; and 80 healthy age- and sex-matched controls. Serum OPN was measured by ELISA. The OPN distribution in the pooled data was divided into quartiles; significant trends across increasing quartiles were estimated by the Cochran-Armitage trend test. Compared with the controls, circulating OPN concentrations were significantly elevated in NAFLD patients and T2DM patients with or without NAFLD. Serum OPN levels were higher in the overweight/obese group than that in the lean group. Circulating OPN levels were positively correlated with CRP, age, BMI, SBP, DBP, HbA1c, UA, TGs, WBCs, neutrophils, FBG, and HOMA-IR and negatively correlated with ADP, albumin and HDL. Age, albumin, HbA1c, HDL and hsCRP were independently related to circulating OPN. The relative risks for NAFLD, T2DM and T2DM with NAFLD increased significantly along with increasing OPN quartiles based on the Cochran-Armitage trend test. OPN is an optimal predictor in the diagnosis of T2DM with NAFLD and T2DM and may contribute to the aggravation of the metabolic state.
引用
收藏
页数:6
相关论文
共 50 条
[31]   Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes [J].
Cho, Yoosun ;
Chang, Yoosoo ;
Ryu, Seungho ;
Wild, Sarah H. ;
Byrne, Christopher D. .
LIVER INTERNATIONAL, 2023, 43 (11) :2445-2454
[32]   The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus [J].
Zhang, Xueyang ;
Bai, Ran ;
Jia, Yong ;
Zong, Junwei ;
Wang, Yongbo ;
Dong, Yanan .
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2020, 40 (04) :491-499
[33]   Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: The Hidden Epidemic [J].
Ismail, Mona H. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (06) :485-492
[34]   The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial [J].
Khaliq, Adil ;
Badshah, Haroon ;
Shah, Yasar ;
Rehman, Inayat Ur ;
Khan, Kashif Ullah ;
Ming, Long Chiau ;
Cheng, Maong Hui .
MEDICINE, 2024, 103 (45) :e40356
[35]   Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease [J].
Adrian, Therese ;
Hornum, Mads ;
Knop, Filip Krag ;
Almdal, Thomas ;
Rossing, Peter ;
Lida, Lisa ;
Heinrich, Niels Sondergaard ;
Boer, Vincent Oltman ;
Marsman, Anouk ;
Petersen, Esben Thade ;
Siebner, Hartwig Roman ;
Feldt-Rasmussen, Bo .
NEPHRON, 2023, 147 (06) :317-328
[36]   Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes [J].
Zhao, Cui-Chun ;
Wang, Ai-Ping ;
Li, Lian-Xi ;
Li, Ting-Ting ;
Chen, Ming-Yun ;
Zhu, Yue ;
Yu, Tian-Pei ;
Bao, Yu-Qian ;
Jia, Wei-Ping .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (06) :1074-1080
[37]   Hepatotoxicity Associated with Metformin Therapy in Treatment of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease [J].
Cone, Catherine J. ;
Bachyrycz, Amy M. ;
Murata, Glen H. .
ANNALS OF PHARMACOTHERAPY, 2010, 44 (10) :1655-1659
[38]   Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus [J].
Fukuhara, Takayuki ;
Hyogo, Hideyuki ;
Ochi, Hidenori ;
Fujino, Hatsue ;
Kan, Hiromi ;
Naeshiro, Noriaki ;
Honda, Yohji ;
Miyaki, Daisuke ;
Kawaoka, Tomokazu ;
Tsuge, Masataka ;
Hiramatsu, Akira ;
Imamura, Michio ;
Kawakami, Yoshiiku ;
Aikata, Hiroshi ;
Chayama, Kazuaki .
HEPATO-GASTROENTEROLOGY, 2014, 61 (130) :323-328
[39]   Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease [J].
Mantovani, Alessandro ;
Targher, Giovanni .
ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (13)
[40]   Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease [J].
Karamfilova, Vera ;
Assyov, Yavor ;
Nedeva, Iveta ;
Gateva, Antoaneta ;
Ivanova, Irena ;
Cherkezov, Nikolay ;
Mateva, Ludmila ;
Kamenov, Zdravko .
METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (02) :132-136